Imotopes: An immunotherapy animation of new immunotherapeutics

Nov 1, 2019 | Projects

Imotopes: An immunotherapy animation of new immunotherapeutics

ABOUT

[/vc_column_text][/vc_column][vc_column width=”6/12″][vc_column_text]–

CLIENT: [/vc_column_text][vc_column_text]

Imcyse is a clinical-stage biotech company created in 2010 as a spin-off of the Catholic University of Leuven, aiming to develop the next generation of therapeutic biologics.

[/vc_column_text][/vc_column][vc_column width=”6/12″][vc_column_text]–

SERVICE: [/vc_column_text][vc_column_text]At 3DforScience we turned the client illustrations into easily understandable 3D scientific animation explaining their disruptive approach through an immunotherapy animation.[/vc_column_text][/vc_column][vc_column][us_separator size=”small”][vc_column_text]–

Imcyse is developing a new class immunotherapeutic molecule: Imotopes. This new technology is the combination of target antigenic natural HLA-Class II peptidic epitopes with a specific thioredox motif.

As a result of this specific composition, the interaction between Imotopes and the antigen-specific T-cells induce lysis of a significant part of cells associated with the autoimmune response.

Therefore, these modified peptides successfully block the autoimmune response without affecting the other functions of the immune system. Thus, representing major progress for the treatment of autoimmune degenerative diseases such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis.[/vc_column_text][us_separator][/vc_column][/vc_row][vc_row][vc_column][us_separator size=”small”][/vc_column][vc_column width=”2/3″][vc_column_text]

ARE YOU INTERESTED IN SCIENTIFIC ANIMATION AND COMMUNICATION?

[/vc_column_text][/vc_column][vc_column width=”1/3″][us_btn label=”Contact us” link=”url:https%3A%2F%2F3dforscience.com%2F%23contact%20_blank||target:%20_blank|”][/vc_column][vc_column][us_separator size=”small”][/vc_column][/vc_row]

ARE YOU INTERESTED IN SCIENTIFIC ANIMATION AND COMMUNICATION?

Related news

High performance sustainable material: Sappi Symbio

High performance sustainable material: Sappi Symbio

High performance sustainable material: Sappi Symbio Sappi is a global company focused on providing dissolving pulp, paper pulp, paper-based and biorefinery solutions to its customers in over 150 countries. They invest in research and development programs, unlocking...

cPass™ technology by GenScript

cPass™ technology by GenScript

cPass™ Technology by GenScript Coronaviruses are a large family of viruses that may cause illness in animals or humans.  In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East...

B2B device: from breast to bone

B2B device: from breast to bone

B2B Device: From Breast To Bone ABOUT CLIENT: B2B is an EU-funded project that aims to develop a breakthrough technology that for the first time dissects the steps of spontaneous breast cancer metastasis to the bone and captures the 3D complexity of the process. The...